학술논문

A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma
Document Type
Article
Source
In: Cancer Science. (Cancer Science, 1 October 2020, 111(10):3759-3769)
Subject
Language
English
ISSN
13497006
13479032